Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study.
about
Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sorafenib in metastatic uveal ...... a multicentre phase II study.
@en
Sorafenib in metastatic uveal ...... a multicentre phase II study.
@nl
type
label
Sorafenib in metastatic uveal ...... a multicentre phase II study.
@en
Sorafenib in metastatic uveal ...... a multicentre phase II study.
@nl
prefLabel
Sorafenib in metastatic uveal ...... a multicentre phase II study.
@en
Sorafenib in metastatic uveal ...... a multicentre phase II study.
@nl
P2093
P2860
P50
P356
P1476
Sorafenib in metastatic uveal ...... n a multicentre phase II study
@en
P2093
C Delcambre
C Dutriaux
E M Neidhart-Berard
F Mouriaux
J J Parienti
S Piperno-Neumann
T Lesimple
P2860
P2888
P356
10.1038/BJC.2016.119
P407
P577
2016-06-02T00:00:00Z